Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 101

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 101
---
internal controls and procedures over financial reporting could severely inhibit our ability to accurately report our financial condition,
results of operations or cash flows.

We are incurring increased costs as a result of operating as a public company, and management will be required to devote substantial time to new compliance initiatives.

We are a public company, and
as such we are incurring significant legal, accounting and other expenses that we did not incur as a private company. We are currently
subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act,
as well as rules adopted, and to be adopted, by the SEC and the NASDAQ. Our management and other personnel will need to devote a substantial
amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and
financial compliance costs and to make some activities more time-consuming and costly. For example, we expect these rules and regulations
to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur
substantial costs to maintain the sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur
to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified
persons to serve on our Board of Directors, our board committees or as members of our senior management.

| 50 |

Risks Related to Investing in a Foreign Private Issuer or United Kingdom Company

We are a “foreign private issuer” under the rules and regulations of the SEC and, as a result, are exempt from a number of rules under the Exchange Act and are permitted to file less information with the SEC than a company incorporated in the United States.

We are incorporated as a public
limited company in England and Wales and are deemed to be a “foreign private issuer” under the rules and regulations of the
SEC. As a foreign private issuer, we are exempt from certain rules under the Exchange Act that would otherwise apply if we were a company
incorporated in the United States, including:

| • | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| • | the requirement to file financial statements prepared in accordance with U.S. GAAP; |

| • | the proxy rules, which impose certain disclosure and procedural requirements for proxy or consent solicitations;